The failing heart as a drug target: are we finally seeing progress?
Mucke
Hermann A M
HA
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000818:Animals; D053818:Chymases; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D015195:Drug Design; D006333:Heart Failure / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D009206:Myocardium / Q000473:pathology; D011480:Protease Inhibitors / Q000627:therapeutic use; D012697:Serine Endopeptidases / Q000502:physiology
D011480:Protease Inhibitors; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D012697:Serine Endopeptidases; D053818:Chymases